Quick Answer
Jade Biosciences, Inc. reported Operating Income Loss of -$113.54 million for the year ending 2025.
- Jade Biosciences, Inc. showed a decrease of -52.2% in Operating Income Loss from 2024 to 2025.
- This data is from Jade Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$1.63 million | Q3 2020: -$2.24 million | Q1 2021: -$2.78 million | Q2 2021: -$5.77 million | Q3 2021: -$6.20 million | Q1 2022: -$11.02 million | Q2 2022: -$12.22 million | Q3 2022: -$14.15 million | Q1 2023: -$17.64 million | Q2 2023: -$20.34 million | Q3 2023: -$21.37 million | Q1 2024: -$24.62 million | Q2 2024: -$26.17 million | Q2 2024: -$590.0 thousand | Q3 2024: -$14.97 million | Q1 2025: -$3.39 million | Q2 2025: -$27.78 million | Q3 2025: -$27.40 million.
- Over the full 6 years of available data (2020 to 2025), Jade Biosciences, Inc.'s Operating Income Loss has declined by 1,177.3%.
- Historical annual values: Fiscal year 2025: -$113.54 million | Fiscal year 2024: -$74.60 million | Fiscal year 2023: -$81.41 million | Fiscal year 2022: -$53.24 million | Fiscal year 2021: -$23.02 million | Fiscal year 2020: -$8.89 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: